Androgen, Estrogen, and Stem Cell Markers Help Predict Recurrence and Survival in Metastatic Prostate Cancer


Get Permission

In a study reported in Clinical Cancer Research, Fujimura and colleagues developed and tested models to predict prostate-specific antigen (PSA) recurrence and cancer-specific survival in patients with treatment-naive prostate cancer and bone metastases using mRNA expression of genes involved in androgen and estrogen signaling and genes in stem cell-like cells.

Cancer and stromal tissues were collected via laser-captured microdissection. Markers analyzed for association with clinical outcome consisted of: androgen receptor and related genes APP, FOX family, TRIM36, Oct1, and ACSL3; stem cell-like cell genes Klf4, c-Myc, Oct3/4, and Sox2; estrogen receptor (ER) and Her2 expression; and PSA and C-reactive protein (CRP).

Analysis of the ability to predict PSA recurrence showed an area under the curve value of 1.0 in both training (n = 46) and validation (n = 30) cohorts for Sox2, Her2, and CRP expression in cancer cells, androgen receptor and ERα expression in stromal cells, and clinical parameters. A model using Oct1, TRIM36, Sox2, and c-Myc expression in cancer cells, androgen receptor, Klf4, and ERα expression in stromal cells, PSA, Gleason score, and extent of disease identified favorable-, intermediate-, and poor-risk groups, with 5-year cancer-specific survival rates of 90%, 32%, and 12% in the training set and 75%, 48%, and 0% in the validation set.

The investigators concluded, “Expression levels of androgen and estrogen signaling components and [stem cell] markers are powerful prognostic tools.” ■

Fujimura T, et al: Clin Cancer Res. July 1, 2014 (early release online).


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.